LLNI Funded Publications
Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Author:Chan KK
Other Authors: Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR,
Last Updated:04/08/2019
Source:PubMed
Original Source:PubMed
Type:Journal Article
DOI:10.18632/oncotarget.16368
Journal:Oncotarget
Volume:8
Issue:24
Pages:38251-38263
Date: June 2017
